Published in Eur Respir J on February 01, 2003
The SF-36 and SGRQ: validity and first look at minimum important differences in IPF. Respir Med (2009) 2.18
Efficacy and safety of NVA237 versus placebo and tiotropium in patients with COPD: the GLOW2 study. Eur Respir J (2012) 1.98
Efficacy and safety of once-daily NVA237 in patients with moderate-to-severe COPD: the GLOW1 trial. Respir Res (2011) 1.89
Once-daily NVA237 improves exercise tolerance from the first dose in patients with COPD: the GLOW3 trial. Int J Chron Obstruct Pulmon Dis (2012) 1.52
Efficacy and safety of tiotropium Respimat SMI in COPD in two 1-year randomized studies. Int J Chron Obstruct Pulmon Dis (2010) 1.51
Outcome measures in chronic obstructive pulmonary disease (COPD): strengths and limitations. Respir Res (2010) 1.31
A blinded evaluation of the efficacy and safety of glycopyrronium, a once-daily long-acting muscarinic antagonist, versus tiotropium, in patients with COPD: the GLOW5 study. BMC Pulm Med (2014) 1.21
Impact of frequency of COPD exacerbations on pulmonary function, health status and clinical outcomes. Int J Chron Obstruct Pulmon Dis (2009) 1.19
Comparative efficacy of long-acting bronchodilators for COPD: a network meta-analysis. Respir Res (2013) 1.12
New combination bronchodilators for chronic obstructive pulmonary disease: current evidence and future perspectives. Br J Clin Pharmacol (2015) 1.10
COPD management: role of symptom assessment in routine clinical practice. Int J Chron Obstruct Pulmon Dis (2013) 1.09
Comparative efficacy of indacaterol 150 μg and 300 μg versus fixed-dose combinations of formoterol + budesonide or salmeterol + fluticasone for the treatment of chronic obstructive pulmonary disease--a network meta-analysis. Int J Chron Obstruct Pulmon Dis (2011) 0.97
Indacaterol on dyspnea in chronic obstructive pulmonary disease: a systematic review and meta-analysis of randomized placebo-controlled trials. BMC Pulm Med (2013) 0.94
Measures of dyspnea in pulmonary rehabilitation. Multidiscip Respir Med (2010) 0.93
Improving the quality of life in patients with chronic obstructive pulmonary disease: focus on indacaterol. Int J Chron Obstruct Pulmon Dis (2013) 0.92
Efficacy and safety of coadministration of once-daily indacaterol and glycopyrronium versus indacaterol alone in COPD patients: the GLOW6 study. Int J Chron Obstruct Pulmon Dis (2014) 0.91
Profile of glycopyrronium for once-daily treatment of moderate-to-severe COPD. Int J Chron Obstruct Pulmon Dis (2012) 0.89
A randomized, blinded study to evaluate the efficacy and safety of umeclidinium 62.5 μg compared with tiotropium 18 μg in patients with COPD. Int J Chron Obstruct Pulmon Dis (2016) 0.88
Clinical trial design in chronic obstructive pulmonary disease: current perspectives and considerations with regard to blinding of tiotropium. Respir Res (2012) 0.87
Clinical trials in systemic sclerosis: lessons learned and outcomes. Arthritis Res Ther (2007) 0.84
Chronic obstructive pulmonary disease in China: the potential role of indacaterol. J Thorac Dis (2013) 0.83
Long-term efficacy of intensive cycle ergometer exercise training program for advanced COPD patients. Int J Chron Obstruct Pulmon Dis (2015) 0.83
Indacaterol for chronic obstructive pulmonary disease: systematic review and meta-analysis. PLoS One (2013) 0.83
Extrafine beclomethasone/formoterol compared to fluticasone/salmeterol combination therapy in COPD. BMC Pulm Med (2014) 0.81
Quality of life and dyspnoea in patients treated with bosentan for idiopathic pulmonary fibrosis (BUILD-1). Eur Respir J (2009) 0.80
Safety and efficacy of 12-week or longer indacaterol treatment in moderate-to-severe COPD patients: a systematic review. Lung (2013) 0.80
Prevention of clinically important deteriorations in COPD with umeclidinium/vilanterol. Int J Chron Obstruct Pulmon Dis (2016) 0.79
Effects of Adding Tiotropium or Aclidinium as Triple Therapy Using Impulse Oscillometry in COPD. Lung (2016) 0.77
Does roflumilast improve dyspnea in patients with chronic obstructive pulmonary disease? A meta-analysis. J Thorac Dis (2013) 0.77
Patient-reported outcomes and considerations in the management of COPD: focus on aclidinium. Patient Prefer Adherence (2015) 0.77
Noninvasive positive pressure ventilation in subjects with stable COPD: a randomized trial. Int J Chron Obstruct Pulmon Dis (2013) 0.77
Nebulized formoterol: a review of clinical efficacy and safety in COPD. Int J Chron Obstruct Pulmon Dis (2010) 0.76
A randomised, open-label study of umeclidinium versus glycopyrronium in patients with COPD. ERJ Open Res (2016) 0.76
The lungs need to be deflated: effects of glycopyrronium on lung hyperinflation in COPD patients. Multidiscip Respir Med (2014) 0.75
Quality of life in patients with chronic thromboembolic pulmonary hypertension. Eur Respir J (2016) 0.75
The effect of umeclidinium added to inhaled corticosteroid/long-acting β2-agonist in patients with symptomatic COPD: a randomised, double-blind, parallel-group study. NPJ Prim Care Respir Med (2016) 0.75
Efficacy and safety of tiotropium + olodaterol maintenance treatment in patients with COPD in the TONADO(®) and OTEMTO(®) studies: a subgroup analysis by age. Int J Chron Obstruct Pulmon Dis (2016) 0.75
Effect of tiotropium and olodaterol on symptoms and patient-reported outcomes in patients with COPD: results from four randomised, double-blind studies. NPJ Prim Care Respir Med (2017) 0.75
Safety and Performance Characteristics of Outpatient Medical Thoracoscopy and Indwelling Pleural Catheter Insertion for Evaluation and Diagnosis of Pleural Disease at a Tertiary Center in Canada. Can Respir J (2017) 0.75
Outcomes for COPD pharmacological trials: from lung function to biomarkers. Eur Respir J (2008) 5.38
The measurement of dyspnea. Contents, interobserver agreement, and physiologic correlates of two new clinical indexes. Chest (1984) 5.19
A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J (2002) 4.68
Salmeterol plus theophylline combination therapy in the treatment of COPD. Chest (2001) 2.01
Dyspnea ratings for prescription of cross-modal exercise in patients with COPD. Chest (1998) 1.54
Clinical and roentgenographic features of nosocomial pulmonary disease due to Mycobacterium xenopi. Am Rev Respir Dis (1981) 1.32
Sustained-release theophylline reduces dyspnea in nonreversible obstructive airway disease. Am Rev Respir Dis (1985) 1.30
Respiratory muscle fatigue after marathon running. J Appl Physiol Respir Environ Exerc Physiol (1982) 1.08
Effects of arformoterol twice daily, tiotropium once daily, and their combination in patients with COPD. Respir Med (2009) 1.07
Targeted inspiratory muscle training improves respiratory muscle function and reduces dyspnea in patients with chronic obstructive pulmonary disease. Ann Intern Med (1989) 1.06
Air-fluid levels within lung bullae associated with pneumonitis. Lung (1981) 1.03
Comparison of clinical dyspnea ratings and psychophysical measurements of respiratory sensation in obstructive airway disease. Am Rev Respir Dis (1987) 1.01
Peri-emphysematous lung infection. Clin Chest Med (1981) 0.98
Descriptors of breathlessness in healthy individuals: distinct and separable constructs. Chest (2000) 0.97
Exercise impairment in chronic obstructive pulmonary disease. Clin Chest Med (1984) 0.95
Dyspnea ratings for prescribing exercise intensity in patients with COPD. Chest (1996) 0.92
Physiologic changes in rowing performance associated with training in collegiate women rowers. Int J Sports Med (1985) 0.91
Right and left ventricular exercise performance in chronic obstructive pulmonary disease: radionuclide assessment. Ann Intern Med (1980) 0.91
Right ventricular performance and central circulatory hemodynamics during upright exercise in patients with chronic obstructive pulmonary disease. Am Rev Respir Dis (1984) 0.88
Target dyspnea ratings predict expected oxygen consumption as well as target heart rate values. Am J Respir Crit Care Med (1999) 0.87
Comparison of 6-min "all-out" and incremental exercise tests in elite oarsmen. Med Sci Sports Exerc (1984) 0.86
Volumetric responses of right and left ventricles during upright exercise in normal subjects. J Appl Physiol (1985) (1985) 0.85
Salmeterol reduces dyspnea and improves lung function in patients with COPD. Chest (1997) 0.85
Mechanical and physiological evaluation of exercise performance in elite national rowers. JAMA (1984) 0.85
Intratumoral Bacillus Calmette-Guérin immunotherapy prior to surgery for carcinoma of the lung: results of a prospective randomized trial. Cancer Res (1986) 0.84
Acute effects of passive smoking on lung function and airway reactivity in asthmatic subjects. Chest (1986) 0.84
Pathophysiology of dyspnea. Monaldi Arch Chest Dis (2001) 0.83
The aging lung. Clin Geriatr Med (1986) 0.82
Ventilatory responses at rest and during exercise in marathon runners. J Appl Physiol Respir Environ Exerc Physiol (1982) 0.82
Aging and exercise performance. Clin Geriatr Med (1986) 0.81
Dyspnea: mechanisms, evaluation and treatment. Am Rev Respir Dis (1988) 0.81
Does entrained breathing improve the economy of rowing? Med Sci Sports Exerc (1994) 0.80
Comparison of dyspnea ratings during submaximal constant work exercise with incremental testing. Med Sci Sports Exerc (1998) 0.80
Lung function after marathon running at warm and cold ambient temperatures. Am Rev Respir Dis (1981) 0.80
Relationship between oxygen uptake and oxygen transport in stable patients with chronic obstructive pulmonary disease. Physiologic effects of nitroprusside and hydralazine. Am Rev Respir Dis (1984) 0.79
Do you speak the language of dyspnea? Chest (2000) 0.79
Effectiveness of salmeterol versus ipratropium bromide on exertional dyspnoea in COPD. Eur Respir J (2001) 0.78
Evaluation of dyspnea in the elderly patient. Clin Chest Med (1993) 0.78
Right ventricular function at rest and during exercise in chronic obstructive pulmonary disease. Chest (1992) 0.78
Pulmonary function in runners before and after a 20 kilometer road race. Conn Med (1980) 0.78
Dyspnea: diagnosis and management. Clin Chest Med (1987) 0.78
The role of theophylline in the treatment of dyspnea in COPD. Chest (1987) 0.77
Determination of cardiac output at rest and during exercise by carbon dioxide rebreathing method in obstructive airway disease. Am Rev Respir Dis (1985) 0.76
Cardiovascular responses to rowing. Med Sci Sports Exerc (1987) 0.75
Pulmonary dysfunction in ultramarathon runners. Yale J Biol Med (1982) 0.75
Use of the breathing reserve to interpret submaximal exercise responses. Chest (1998) 0.75
Looped bronchoscope. Chest (1978) 0.75
Effect of exercise training on dyspnea measures in patients with chronic obstructive pulmonary disease. J Cardiopulm Rehabil (1997) 0.75
Letter: Jimson weed seeds. Ann Intern Med (1975) 0.75
Controversies in pulmonary medicine. Respiratory muscle training should be instituted in all COPD patients. Am Rev Respir Dis (1988) 0.75
Positional dyspnea and oxygen desaturation related to carcinoma of the lung. Up with the good lung. Chest (1983) 0.75
Letter: The Jimson-weed high. JAMA (1975) 0.75
Exercise performance in marathon runners with airway obstruction. Med Sci Sports Exerc (1981) 0.75
Anticholinergic poisoning from Jimson weed. JACEP (1976) 0.75
The physiology of endurance exercise. The marathon. Clin Chest Med (1984) 0.75
Chronic obstructive pulmonary disease. Clin Geriatr Med (1986) 0.75
Rabies in Delaware. Del Med J (1974) 0.75
The Physiology of Marathon Running. Phys Sportsmed (1985) 0.75
The Migrant Health Clinic in Dover. Del Med J (1975) 0.75
Diagnosis of chronic obstructive pulmonary disease and differentiation from asthma. Curr Opin Pulm Med (1995) 0.75
Theophylline improves global cardiac function and reduces dyspnea in chronic obstructive lung disease. J Allergy Clin Immunol (1986) 0.75